|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
G12D and Q61H are among the most prevalent cancer-causing mutations at the P-loop and switch 2 regions of KRAS, respectively.
|
31554397 |
2019 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, we use the LITer gene circuit architecture to control gene expression of the cancer oncogene KRAS(G12V) and study its downstream effects through phospho-ERK levels and cellular proliferation.
|
31269201 |
2019 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Adenoviral vectors containing the specific ribozymes with downstream suicide gene were constructed and then infection with the adenoviruses specifically downregulated KRAS G12V expression and killed KRAS G12V-harboring cancer cells additively upon pro-drug treatment, but it did not affect the growth of wild-type KRAS-expressing cells.
|
28153088 |
2017 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After subsequent sequence optimization, we successfully generated KRpep-2d (Ac-RRRRCPLYISYDPVCRRRR-NH<sub>2</sub>) that inhibited enzyme activity of K-Ras(G12D) with IC<sub>50</sub> = 1.6 nM and significantly suppressed ERK-phosphorylation, downstream of K-Ras(G12D), along with A427 cancer cell proliferation at 30 μM peptide concentration.
|
28153726 |
2017 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
|
27959684 |
2016 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, our results illustrate that the K-Ras(V14I) activating protein is able to induce cancer, although at a much lower level than the classical K-Ras(G12V) oncogene, and that it can be significantly modulated by both genetic and non-genetic events.
|
27174785 |
2016 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although mutations in known driver genes typically occurred early in cancer evolution, we also identified later subclonal "actionable" mutations, including BRAF (V600E), IDH1 (R132H), PIK3CA (E545K), EGFR (L858R), and KRAS (G12D), which may compromise the efficacy of targeted therapy approaches.
|
25877892 |
2015 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we globally activated a mutant oncogenic K-Ras allele (K-Ras(G12D)) in mice and examined the tissue-specific effects of this activation on cancer pathobiology, Ras signaling, tumor suppressor, DNA damage, and inflammatory responses.
|
22532587 |
2012 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, all mice with Kras(G12D) activation and Pten homozygous deletion succumbed to cancer by 3 weeks of age.
|
20807812 |
2010 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The codon 12 G12D mutation was found; the same mutation was evident in the primary cancer of the colon and in its liver and lung metastasis.
|
20213843 |
2010 |
|
rs121913529
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most common mutation K-Ras(G12V), required for tumor proliferation, survival, and metastasis due to its constitutively active GTPase activity, has provided an ideal target for cancer therapy.
|
19014906 |
2009 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Additionally, the specific p.G12R NRAS mutation in this case is a common somatic mutation in cancer cells, and analysis of previously reported NRAS-RASopathy cases suggests that mutations at traditionally oncogenic codons are associated with elevated cancer risk not present with mutations at other sites.
|
31697451 |
2020 |
|
rs712
|
|
|
0.040 |
GeneticVariation |
BEFREE |
As an indicator for the malignancy of thyroid nodules (TN), the doubling time of TN was studied in this study to evaluate the effect of rs712 polymorphism on the progression of TN.
|
31152438 |
2019 |
|
rs712
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The rs712 polymorphism in a let-7 microRNA-binding site at <i>KRAS</i> gene has been associated with cancer.
|
31156795 |
2019 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
G12D, G12V, G12C) of V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras), the most promising drug target in cancer therapy, are major growth drivers in various cancers.
|
28153726 |
2017 |
|
rs61764370
|
|
|
0.040 |
GeneticVariation |
BEFREE |
These results indicated that genotype.GT/GG of rs61764370 was not a genetic susceptible risk factor for cancer, and rs61764370 could not be used as a biomarker for estimating cancer risk in Caucasian population.
|
27461636 |
2017 |
|
rs712
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis.
|
28099923 |
2017 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our result highlighted that the gross metabolic changes observed in G12C KRAS mutant cells growing in culture were also maintained in the derived xenograft model, suggesting that a simple in vitro cell model can give important insights into the metabolic alterations induced by cancer.
|
27329432 |
2016 |
|
rs61764370
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We conclude that KRAS rs61764370 polymorphism is significantly associated with risk and prognosis of gallbladder malignancy in this endemic belt.
|
27620744 |
2016 |
|
rs712
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The findings suggested that allele T, genotype TT and allele T carrier (GT/TT) of rs712 may increase susceptibility to cancer risk in Chinese population, and can be used as a genetic factor for evaluating risk of cancer.
|
25778332 |
2015 |
|
rs61764370
|
|
|
0.040 |
GeneticVariation |
BEFREE |
These results suggest that the cancer-associated rs61764370 variant exerts a biological effect not through transcriptional modulation of KRAS but rather by tuning the expression of the microRNA let-7.
|
24282149 |
2014 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
GeLC-MRM detected KRAS mutant variants (G12D, G13D, G12V, G12S) in a panel of cancer cell lines.
|
22671702 |
2012 |
|
rs61764370
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We previously identified a functional variant in a let-7 microRNA (miRNA) complementary site in the 3'-untranslated region of the KRAS oncogene (rs61764370) which is associated with cancer.
|
21435948 |
2011 |
|
rs17851045
|
|
|
0.010 |
GeneticVariation |
BEFREE |
G12D and Q61H are among the most prevalent cancer-causing mutations at the P-loop and switch 2 regions of KRAS, respectively.
|
31554397 |
2019 |
|
rs953088090
|
|
|
0.010 |
GeneticVariation |
BEFREE |
KRAS E63K is curated in the Catalogue of Somatic Mutations in Cancer database.
|
31289513 |
2019 |